About: Inclisiran

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.

Property Value
dbo:abstract
  • Inclisiran (Handelsname Leqvio) ist ein Arzneistoff zur Behandlung erhöhter Cholesterinspiegel (Hypercholesterinämie) oder der gemischten Dyslipidämie (Fettstoffwechselstörung einhergehend mit zu hohen Spiegeln von Lipiden wie Cholesterin und Triglyzeriden oder beidem). Es gehört zur Gruppe der RNAi-Therapeutika. (de)
  • Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9. Inclisiran was approved for use in the European Union in December 2020. In August 2021, it received NICE approval for use by the National Health Service in the UK. In December 2021, it was approved for medical use in the United States. (en)
  • L'inclisiran est un petit ARN interférent dirigé contre l'ARN du PCSK9, en cours de test dans les hypercholestérolémies. (fr)
  • Inclisiran, commercializzato con il nome Leqvio, è un farmaco per la riduzione effiace e sostenuta nel tempo del colesterolo LDL. Inclisiran è indicato il trattamento della malattia cardiovascolare aterosclerotica e dell'ipercolesterolemia familiare eterozigote in aggiunta al controllo dietetico e a una statina o in alternativa alle statine laddove esse siano controindicate o non tollerate. Si tratta del primo siRNA che riduce la traduzione della proteina PCSK9. LEQVIO è commercializzato in Europa da Novartis. (it)
dbo:alternativeName
  • Leqvio (en)
dbo:casNumber
  • 1639324-58-5
dbo:chEBI
  • 176399
dbo:drugbank
  • DB14901
dbo:fdaUniiCode
  • UOW2C71PG5
dbo:kegg
  • D11931
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 55572620 (xsd:integer)
dbo:wikiPageLength
  • 15831 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1107260491 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • 10.0
dbp:atcSuffix
  • AX16 (en)
dbp:c
  • 520 (xsd:integer)
dbp:casNumber
  • 1639324 (xsd:integer)
dbp:chebi
  • 176399 (xsd:integer)
dbp:dailymedid
  • Inclisiran (en)
dbp:date
  • August 2022 (en)
dbp:drugbank
  • DB14901 (en)
dbp:f
  • 21 (xsd:integer)
dbp:h
  • 679 (xsd:integer)
dbp:kegg
  • D11931 (en)
dbp:legalAu
  • S4 (en)
dbp:legalCa
  • Rx-only (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalUs
  • Rx-only (en)
dbp:n
  • 175 (xsd:integer)
dbp:o
  • 309 (xsd:integer)
dbp:p
  • 43 (xsd:integer)
dbp:pregnancyAu
  • B1 (en)
dbp:routesOfAdministration
dbp:s
  • 6 (xsd:integer)
dbp:small
  • no (en)
dbp:synonyms
  • ALN-PCSsc, ALN-60212 (en)
dbp:tradename
  • Leqvio (en)
dbp:unii
  • UOW2C71PG5 (en)
dbp:wikiPageUsesTemplate
dbp:with
  • secondary source-derived descriptions of the class of this agent, information on its discovery, and its mechanism of action (en)
dcterms:subject
rdf:type
rdfs:comment
  • Inclisiran (Handelsname Leqvio) ist ein Arzneistoff zur Behandlung erhöhter Cholesterinspiegel (Hypercholesterinämie) oder der gemischten Dyslipidämie (Fettstoffwechselstörung einhergehend mit zu hohen Spiegeln von Lipiden wie Cholesterin und Triglyzeriden oder beidem). Es gehört zur Gruppe der RNAi-Therapeutika. (de)
  • L'inclisiran est un petit ARN interférent dirigé contre l'ARN du PCSK9, en cours de test dans les hypercholestérolémies. (fr)
  • Inclisiran, commercializzato con il nome Leqvio, è un farmaco per la riduzione effiace e sostenuta nel tempo del colesterolo LDL. Inclisiran è indicato il trattamento della malattia cardiovascolare aterosclerotica e dell'ipercolesterolemia familiare eterozigote in aggiunta al controllo dietetico e a una statina o in alternativa alle statine laddove esse siano controindicate o non tollerate. Si tratta del primo siRNA che riduce la traduzione della proteina PCSK9. LEQVIO è commercializzato in Europa da Novartis. (it)
  • Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9. (en)
rdfs:label
  • Inclisiran (de)
  • Inclisiran (en)
  • Inclisiran (fr)
  • Inclisiran (it)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License